ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenAthebio AG
Athebio AG Logo
Verified· 3 sources

Athebio AG

Summary

About the company

The core activity of Athebio AG is the development and provision of proprietary technology for the creation of targeted therapeutics with improved efficacy and safety, particularly through the use of "plug & play" DARPin technology (Athebody). The company focuses on partnering with pharmaceutical companies to develop and market innovative medicines.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered7
Athebody® platform
Athebody® DARPin platform for targeted biotherapeutics, with modular binding domains, high specificity, solubility and stability, as well as multi-specificity and protein fusion options.
Drug-Discovery-Engine
In-vitro discovery engine for the selection of binders with controlled target quality and high library diversity for preclinical and clinical development.
Partnering for biotherapeutic development projects
Flexible partnership models, joint project teams, and access to Athebody® technology for drug developers and biotherapeutics development.
Targeted AAV development
Development of targeted adeno-associated viruses for viral gene therapy, for example for neurology and ophthalmology, for directed DNA delivery into target tissues.
Targeted LNP development
Development of targeted lipid nanoparticles for non-viral gene therapy, for directed mRNA delivery into the desired tissue, for example in oncology or infectious diseases.
Press

Media

February 7, 2022Media
Athebio enters collaboration agreement in the field of gene therapy
startupticker.ch

Knowledge

No knowledge articles yet

Once Athebio AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Athebio AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Athebio AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Athebio AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 18
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-259.171.415
Founded
2019 · 7 years
Last commercial register change
December 22, 2025
Employees
21 to 50

Similar companies

AR
Akademische Raumfahrt Initiative Schweiz (ARIS)
Dübendorf
AA
Avientus AG
Zurich
ST
Stiftung Technopark Zürich
Zurich
AC
AlgorithmWatch CH
Zurich